Melanoma GEP: where risk scores help—and where they do not
About 25% of melanoma patients with a high-risk Class 2B result on gene expression profiling (GEP) develop metastasis, Dr. Singh said in an Expert Perspectives episode. The figure applies to a high-risk subset, not every patient with a Class 2B result.
Dr. Singh said this group needs closer imaging follow-up. A low-risk Class 1 result can ease anxiety and burden even when management does not change.
The episode frames GEP as a tool for a defined decision, not a universal melanoma test. Its value depends on selecting a patient whose clinical question the result can answer, then interpreting the report alongside that person’s condition.
Where does GEP fit in stage III melanoma?
Dr. Singh said he does not find GEP useful in stage III melanoma that has already spread to the lymph nodes. In that setting, estimating local recurrence is not typically the clinical question he is trying to answer. His broader guidance is specific: GEP, like any tool, benefits the right patient and requires context.
The stage-specific limit reinforces that selection rule. GEP remains most useful when clinicians apply it to the right patient and read the result in context.
What does a 9.7% risk actually mean?
A report may show an individual patient a 9.7% risk of nodal involvement. The estimate can inform the discussion, but it cannot determine by itself whether to add surgery or imaging. Dr. Singh said those decisions must account for goals of care, overall health and functional status.
He contrasted a 9.7% risk in a fit patient with a 12% risk in someone with poor functional status, saying the figures may carry different meanings. His instruction was to treat the patient in front of you, not the lab value and not the cancer.
The numerical contrast is not an argument against risk estimates. It shows why an absolute percentage cannot carry the same meaning for every patient. Goals, health and function can change what added surgery or imaging is reasonable, so the report informs rather than dictates care.
Why might management stay unchanged?
“Management will not change 100% of the time, and that is expected,” Dr. Singh said. Patients and clinicians can reasonably ask why a newly obtained result does not alter the plan.
For a Class 1 low-risk result, Dr. Singh still considers the report valuable because it eases patient anxiety and burden. He often uses GEP specifically to reduce that anxiety, even when the result prompts no change in surveillance or treatment.
Those uses resolve the apparent paradox. A Class 1 result may reduce anxiety without changing treatment, while a Class 2B result may identify a subset that needs closer imaging. Dr. Singh’s answer is that a useful result and an unchanged plan can coexist.
Which patients need closer imaging?
For the high-risk end of the scale, about 25% of patients with a result such as Class 2B develop metastasis. Dr. Singh said this does not describe every patient; it identifies a subset that needs closer imaging follow-up.
That distinction tempers the 25% figure. It establishes a risk signal, not certainty for an individual. Dr. Singh recommends closer imaging for the affected subset rather than declaring that metastasis will occur in every patient.
Can a low-risk result guarantee a good outcome?
Dr. Singh acknowledged that some patients deemed low risk still have poor outcomes, even though GEP sensitivity and specificity sit in the upper 90s. In those cases, he said, staging had also failed the patient.
High test performance does not remove those exceptions. He nevertheless encourages clinicians to consider GEP, citing the volume of supporting data and its association with improved survival.
The caveat tempers interpretation without negating the broader case for testing. Dr. Singh presents GEP as a tool worth considering, not as a guarantee for every patient.
What does the series examine next?
The final episode, “Combining GEP Testing and ctDNA for High-Risk Melanoma Surveillance,” looks ahead to Dr. Singh’s approach for high-risk patients. In that episode, he explains how he pairs GEP testing with circulating tumor DNA monitoring.
The series therefore moves from limitations to a practical surveillance sequence: decide whether GEP fits, interpret it against patient goals and health, then consider how ctDNA can extend monitoring. His closing message is forward-looking but conditional: use GEP selectively, interpret it in context, and pair it with ctDNA in high-risk melanoma.
Source: dermatologytimes.com
Tom Whitfield
Show full bio
Senior reporter covering companies, deals and strategy in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.